iView Therapeutics
PrivateLast Round
Series A
Extension
Jan 17, 2025
Total Funding Raised
$25.86M
Company Overview
iView Therapeutics operates in Healthcare & Life Sciences and is based in Cranbury, New Jersey. Its latest recorded funding round was a Series A Extension round in January 2025.
iView Therapeutics is a clinical-stage biotechnology company that develops innovative topical drugs and gene therapies for ophthalmology, dermatology, and otolaryngology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iView Therapeutics Comparables
Compare iView Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Claris Bio | 84% | |
| Azura Ophthalmics | 79% | |
| Cloudbreak Pharma Inc. | 79% |
For institutional investors. Book with your work email.
iView Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 17, 2025 | ||||
| Series A | Sep 20, 2021 | ||||
| Grant | Apr 11, 2019 | ||||
| Series A | Jun 27, 2018 | ||||
| Grant | Mar 26, 2018 | ||||
Grant | Sep 12, 2016 |
For institutional investors. Book with your work email.
iView Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| BioAdvance Capital | Series A |
| Cowin Capital | Series A |
| Proxima Ventures Ltd. | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2021
$25M raised from BioAdvance Capital and other investors.
- Mar 26, 2018
$280K grant from National Institute of Allergy and Infectious Diseases.
For institutional investors. Book with your work email.
iView Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iView Therapeutics's valuation, stock price, and market status.
Is iView Therapeutics a public or private company?
iView Therapeutics is a private company.
What is the current stock price of iView Therapeutics?
iView Therapeutics is a private company, so its shares have no public market price. Caplight tracks iView Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iView Therapeutics worth (valuation)?
Valuation information for iView Therapeutics is not publicly available.
Can I buy iView Therapeutics stock?
iView Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iView Therapeutics's last funding round?
iView Therapeutics's most recent funding round was Series A Extension on January 17, 2025.
Who are the main investors in iView Therapeutics?
Key investors in iView Therapeutics include National Institute of Allergy and Infectious Diseases, BioAdvance Capital, Cowin Capital, Proxima Ventures Ltd..
Will iView Therapeutics IPO soon?
No public IPO plans have been announced for iView Therapeutics.
How can I track iView Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in iView Therapeutics's shares on secondary markets.